Compare Church & Dwight Co., Inc. (CHD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Johnson & Johnson — how do they compare? Church & Dwight Co., Inc. trades at $97.12 (market cap $22.61B), while Johnson & Johnson trades at $250.93 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 27× Church & Dwight Co., Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.11%). Which is the better fit depends on your goals.
| CHD | JNJ | |
|---|---|---|
Market Cap | $22.61B | $611.07B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $267.24 |
52-Week Low | $81.60 | $155.17 |
Enterprise Value | $24.31B | $644.01B |
Dividend Yield | 1.29% | 2.11% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $97.16, up 0.83% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with 11.81% net margins and consistent organic growth, supported by strategic acquisitions like Miss Mouth's brand. Analyst consensus remains positive with a $105.60 price target, though cash flow trends show recent negative net flows.
CHD presents a balanced opportunity with solid brand execution and margin expansion potential, offset by cash flow volatility and competitive pressures. The stock's premium valuation requires sustained earnings growth to justify upside, with Q2 2026 earnings on July 31 as a key catalyst.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
